title: Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  Survivin, a newly discovered member of the inhibitor of apoptosis protein family, is suggested to be involved in liver carcinogenesis. The aim was to investigate the clinical significance of survivin expression in resected hepatocellular carcinoma (HCC) and paired adjacent non-tumour tissue.
  
  
  RESULTS
  Immunohistochemistry, reverse transcriptase-polymerase chain reaction and Western blots were used to examine survivin mRNA and protein levels in 94 specimens of HCC tissues at different TNM stages and the data were correlated with the clinicopathological profiles. Patients were categorized into those with high tumour survivin protein levels (T-N >or= -1) and those with low levels (T-N < -1). Follow-up data were collected prospectively. mRNA levels of survivin and its splice variants in tumour tissue were significantly higher than in paired non-tumour tissue. However, survivin protein levels in paired non-tumour tissue were significantly higher than in tumour tissue from all three TNM stages. Additionally, high tumour survivin protein levels (T-N >or= -1) correlated with a better prognosis and low levels (T-N < -1) with a worse survival rate.
  
  
  CONCLUSIONS
  High cytoplasmic survivin protein levels in HCC tissues seem to be an indicator of better prognosis in HCC patients after resection.
authors.affiliation: Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. gychau@vghtpe.gov.tw
authors.forename: G-Y
authors.initials: GY
authors.lastname: Chau
authors.forename: A F-Y
authors.initials: AF
authors.lastname: Lee
authors.forename: S-H
authors.initials: SH
authors.lastname: Tsay
authors.forename: Y-R
authors.initials: YR
authors.lastname: Ke
authors.forename: H-L
authors.initials: HL
authors.lastname: Kao
authors.forename: F-H
authors.initials: FH
authors.lastname: Wong
authors.forename: A-P
authors.initials: AP
authors.lastname: Tsou
authors.forename: Y-P
authors.initials: YP
authors.lastname: Chau
mesh_terms: D017398:Alternative Splicing; D000918:Antibody Specificity; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D017931:DNA Primers / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D017931:DNA Primers; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000077022:Survivin